Can-Fite BioPharma Files 6-K Report

Ticker: CANF · Form: 6-K · Filed: Mar 30, 2026 · CIK: 0001536196

Can-Fite Biopharma LTD. 6-K Filing Summary
FieldDetail
CompanyCan-Fite Biopharma LTD. (CANF)
Form Type6-K
Filed DateMar 30, 2026
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: foreign-issuer, filing-update, press-release

Related Tickers: CANF

TL;DR

Can-Fite BioPharma (CANF) dropped a 6-K filing on 3/30/26 with a press release - check it out.

AI Summary

Can-Fite BioPharma Ltd. filed a Form 6-K on March 30, 2026, reporting information as a foreign issuer. The filing includes a press release dated March 30, 2026, and other related documents. The company's mailing and business address is 26 Ben Gurion Street, Ramat Gan, Israel.

Why It Matters

This filing provides an update from Can-Fite BioPharma Ltd., a foreign issuer, which may contain important operational or strategic information for investors.

Risk Assessment

Risk Level: low — A 6-K filing is typically a routine report for foreign issuers and does not inherently signal high risk.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers which supplements the information required to be filed on an annual basis with the SEC.

What is the CIK number for Can-Fite BioPharma Ltd.?

The CIK number for Can-Fite BioPharma Ltd. is 0001536196.

When was this Form 6-K filed and accepted by the SEC?

The Form 6-K was filed and accepted on March 30, 2026.

What is the SIC code for Can-Fite BioPharma Ltd.?

The SIC code for Can-Fite BioPharma Ltd. is 2834, which corresponds to Pharmaceutical Preparations.

Where is Can-Fite BioPharma Ltd. located?

Can-Fite BioPharma Ltd.'s mailing and business address is 26 Ben Gurion Street, Ramat Gan, L3 5257346.

Filing Stats: 275 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2026-03-30 07:22:12

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: March 30, 2026 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing